Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients

Kaplan M., Yavuz F., Kaplan G. I., BURSA N., VURUŞKAN E., Sucu M.

ANATOLIAN JOURNAL OF CARDIOLOGY, vol.25, no.5, pp.330-337, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.14744/anatoljcardiol.2020.17329
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.330-337
  • Hacettepe University Affiliated: Yes


Objective: Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD.